Lung-MAP Infographics Illustrate How the Trial is Helping Patients

Squamous cell carcinoma of the lung is a deadly cancer killer and like many common solid tumors analysis of no one or even several genes provides a sufficiently comprehensive characterization of the actionable alterations present in a population of patients to ensure a high screen hit rate when evaluating patients for a targeted therapy approach. Rather, multiple genes often altered by one or more classes of DNA changes and often co-occurring are unpredictably altered in any given patient. The comprehensive, broad based nature of FoundationOne testing allowed us to be uniquely suited to provide reliable results across an unprecedented broad swath of predictive biomarkers in a clinically relevant TAT to attract multiple interested pharma partners with distinct therapeutic targets.